Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26718096
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26718096
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Lipids+Health+Dis
2015 ; 14
(ä): 167
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Lipids, blood pressure and kidney update 2015
#MMPMID26718096
Banach M
; Aronow WS
; Serban MC
; Rysz J
; Voroneanu L
; Covic A
Lipids Health Dis
2015[Dec]; 14
(ä): 167
PMID26718096
show ga
The most important studies and guidelines in the topics of lipid, blood pressure
and kidney published in 2015 were reviewed. In lipid research, the IMProved
Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial
revalidated the concept "lower is better" for low density lipoprotein
(LDL)-cholesterol as a target for therapy, increasing the necessity of treatment
the high-risk patients to achieve LDL-C goals. After these results, ezetimibe
might become the preferred additional drug in the combination therapy of lipid
disorders because of oral dosage form and lower acquisition cost. However, for
the statin-intolerant patients and those patients requiring essential reductions
in LDL-C to achieve their goals, new therapies, including PCSK9 inhibitors remain
promising drugs. In blood pressure research, American Heart Association
(AHA)/American College of Cardiology (ACC) 2015 guidelines recommended a target
for blood pressure below 140/90 mmHg in stable or unstable coronary artery
disease patients and below 150/90 mmHg in patients older than 80 years of age,
however the recent results of the Systolic Blood Pressure Intervention Trial
(SPRINT) trial have suggested that there might be significant benefits, taking
into account cardiovascular risk, for hypertensive patients over 50 without
diabetes and blood pressure levels <120/80. In kidney research, reducing the
progression of chronic kidney disease and related complications such as anemia,
metabolic acidosis, bone and mineral diseases, acute kidney injury and
cardiovascular disease is still a goal for clinicians.
|Adrenergic beta-Antagonists/therapeutic use
[MESH]
free
free
free
